Dailypharm Live Search Close

oHCM drug Camzyos's last hurdle to reimb remains high

By Eo, Yun-Ho | translator Alice Kang

24.10.15 05:11:45

°¡³ª´Ù¶ó 0
NHIS decides to extend drug price negotiations for the oHCM drug

Government and pharmaceutical company disagree over patient numbers, etc.


The reimbursement journey for ¡®Camzyos¡¯, which is seeking insurance reimbursement in Korea, is going to be a rocky road until the end.

According to industry sources, the drug pricing negotiations between BMS Pharmaceuticals Korea and the National Health Insurance Service (NHIS) for the obstructive hypertrophic cardiomyopathy (oHCM) drug Camzyos (mavacamten) have been extended after failing to finalize the deal within the deadline.

The deadline extension was primarily due to a disagreement over the number of patients eligible for Camzyos.

Camzyos¡¯ reimbursement journey faced difficulties, receiving a redeliberation decision from the Health Insurance Review and Assessment

Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)